fda restrictions on compounding bpc-157 panel votes to place popular peptide list FDA's own advisory committee voted

FDA's own advisory committee voted 8 6 Thursday. BPC 157, on the compounding list now, for ulcerative colitis. FDA staff argued against it, laid out the data gaps, the whole case. Panel overruled them I just testified at an FDA meeting on whether seven popular peptides should be allowed in compounding. Just last month, FDA medical officers determined that none of the peptides met the agency's A step towards expanded patient access. This will allow patients to have conversations about these compounds in the clinical setting instead of resorting to a gray market without practitioner oversight or monitoring! FDA may take an important step toward opening the peptide floodgates this week

SKU: 21944854265 · From iglepidom.org